{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:44Z","timestamp":1793400704333,"version":"4.5.0"},"reference-count":47,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Development Research"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Non\u2010small cell lung cancer (NSCLC) remains a leading cause of cancer\u2010related mortality, with \u201cepidermal growth factor receptor (EGFR)\u201d mutations playing a pivotal role in tumor progression and carcinogenesis. \u201cThird\u2010generation epidermal growth factor receptor\u2010tyrosine kinase inhibitors (EGFR\u2010TKIs),\u201d such as Osimertinib, have significantly improved treatment outcomes by overcoming resistance mechanisms like the T790M mutation. However, Osimertinib's clinical application is limited by cardiotoxicity concerns, necessitating safer alternatives. Lazertinib, a structurally optimized third\u2010generation EGFR\u2010TKI, exhibits superior selectivity for mutant EGFR while sparing wild\u2010type EGFR, thereby reducing off\u2010target toxicities. This current opinion highlights the pharmacological properties of Lazertinib, its enhanced binding interactions, and its efficacy in overcoming resistance while demonstrating an improved safety profile. Comparative analyses reveal that Lazertinib offers stronger inhibition of key EGFR mutations, superior pharmacokinetics, and lower cardiotoxicity risks compared to Osimertinib. Additionally, Lazertinib's improved central nervous system (CNS) penetration enhances its therapeutic potential in patients with brain metastases. As ongoing clinical trials further elucidate its role, Lazertinib emerges as a promising next\u2010generation EGFR inhibitor, offering a safer and more effective alternative for NSCLC treatment.<\/jats:p>","DOI":"10.1002\/ddr.70153","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T11:01:58Z","timestamp":1757329318000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lazertinib: A Cardio\u2010Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R\/T790M Double\u2010Mutant Tyrosine Kinase\u00a0Resistant Non\u2010Small Cell Lung Cancer"],"prefix":"10.1002","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6917-4610","authenticated-orcid":false,"given":"Chandrakant S.","family":"Gawli","sequence":"first","affiliation":[{"name":"R. C. Patel Institute of Pharmaceutical Education and Research Shirpur Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8399-7618","authenticated-orcid":false,"given":"Narendra R.","family":"Nagpure","sequence":"additional","affiliation":[{"name":"R. C. Patel Institute of Pharmaceutical Education and Research Shirpur Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6138-6435","authenticated-orcid":false,"given":"Bhatu R.","family":"Patil","sequence":"additional","affiliation":[{"name":"R. C. Patel Institute of Pharmaceutical Education and Research Shirpur Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9043-1327","authenticated-orcid":false,"given":"Nobuaki","family":"Ochi","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine 4 Kawasaki Medical School Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-5128","authenticated-orcid":false,"given":"Nagio","family":"Takigawa","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine 4 Kawasaki Medical School Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0920-1266","authenticated-orcid":false,"given":"Harun M.","family":"Patel","sequence":"additional","affiliation":[{"name":"R. C. Patel Institute of Pharmaceutical Education and Research Shirpur Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.70036"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117178"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31891"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.10.006"},{"key":"e_1_2_9_6_1","unstructured":"CHMP. 2015. Assessment Report: TAGRISSO INN\u2010Osimertinib Procedure No. EMEA\/H\/C\/004124\/0000.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/004124\/WC500202024.pdf."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.025"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403614"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000637"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0337"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi092"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01533-x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.069203"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-023-00172-3"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm500973a"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030841"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0533-4"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43046-024-00251-1"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.2c00213"},{"key":"e_1_2_9_20_1","unstructured":"https:\/\/clinicaltrials.gov Accessed on April 26 2025."},{"key":"e_1_2_9_21_1","unstructured":"https:\/\/www.drugs.com\/lazcluze.html Accessed on April 26 2025."},{"key":"e_1_2_9_22_1","unstructured":"Indications and Usage Lazcluze in Combination With Amivantamab Is Indicated for the First\u2010Line Treatment of Adult Patients With Locally Advanced or Metastatic Non\u2010Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 19.2024: 1\u201323.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/219008s000lbl.pdf."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100224"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02219"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1773"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2022.63.9.799"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0573-8"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1177003"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-73080-w"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2019.08.004"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.028"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00662"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.05.027"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.117796"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001242"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2017.10.004"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188967"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.08.017"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy292.011"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10351"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0268-z"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-022-00107-x"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yao.2024.01.008"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00891"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.3223"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2906"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.04.036"}],"container-title":["Drug Development Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.70153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T21:10:38Z","timestamp":1760389838000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/ddr.70153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/ddr.70153"],"URL":"https:\/\/doi.org\/10.1002\/ddr.70153","archive":["Portico"],"relation":{},"ISSN":["0272-4391","1098-2299"],"issn-type":[{"value":"0272-4391","type":"print"},{"value":"1098-2299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70153"}}